We have an industry-leading pipeline of seven potential medicines, including five compounds in phase II development. Altogether we have 17 molecules at our disposal to develop as new HIV treatments.
Clinical development pipeline
| Product |
Class |
Phase |
| 1349572 |
Integrase inhibitor |
II |
| UK-453061 |
NNRTI |
II |
2248761
(IDX899) |
NNRTI |
II |
| PF-232798 |
CCR5 antagonist |
II |
| GSK 1265744 |
Integrase inhibitor |
II |
| 706769 |
CCR5 antagonist |
I |